Chemotherapy drugs like doxorubicin and etoposide work by snapping a cancer cell’s DNA in two. The breaks are supposed to be lethal. But in tumors that overexpress the oncoprotein MYC, and that includes an estimated 70% of all human cancers, according to a widely cited analysis in Nature Reviews Cancer, something else happens: the protein rushes to the scene of the damage and helps stitch the breaks back together. A growing body of mechanistic research now shows that MYC does not just drive cancer growth. It actively shields tumor cells from the very treatments designed to kill them. Disabling that shield could make standard chemotherapy dramatically more effective.
MYC shows up at the crime scene
The most striking new evidence comes from a 2025 preprint that has not yet completed peer review. Researchers found that a specific form of the protein, phosphorylated at serine 62 (pS62-MYC), is physically recruited to double-strand breaks when cells face genotoxic stress. Once there, pS62-MYC interacts with BRCA1 and RAD51, two proteins central to homologous recombination, the cell’s most accurate method for repairing severed chromosomes. When the phosphorylated form was absent or blocked in experiments, repair efficiency dropped and fewer cells survived.
That finding reframes MYC from a passive bystander during DNA damage into something more like a repair coordinator, one that is especially active in cells already under heavy replication stress.
A biochemical buffer zone
A separate line of research, published in Nature Communications in early 2026, adds another layer. That study found MYC increases the chromatin engagement of topoisomerase II-alpha (TOP2A) by altering how the enzyme diffuses along DNA and how large its complexes become. TOP2A matters because it is the direct molecular target of anthracyclines and etoposide. Those drugs work by trapping TOP2A on DNA, converting a normal enzyme into a source of lethal breaks.
If MYC simultaneously boosts TOP2A activity and accelerates the repair of the breaks TOP2A creates, the result is a biochemical buffer zone. MYC-high cells generate more drug-induced damage but also clear it faster, blunting the killing power of the very agents oncologists rely on. The practical implication: tumors with high MYC expression may tolerate doses of chemotherapy that would be catastrophic for normal cells or for cancers with lower MYC levels.
Replication stress: the paradox at MYC’s core
MYC’s relationship with DNA damage is not one-directional. The protein also causes damage. Research published in Nature Communications showed that oncogenic MYC forces excessive cohesin loading onto chromatin in a CTCF-dependent manner, generating replication stress that itself produces DNA breaks. Yet MYC-expressing cells manage to survive that self-inflicted damage, reinforcing the idea that the protein has co-opted protective repair pathways to keep itself and its host cell alive.
A 2025 expert review in Frontiers in Cell and Developmental Biology maps this paradox explicitly: MYC induces genome instability yet promotes repair and survival under DNA damage. The review identifies several actionable nodes in the repair cascade, including ATR, CHK1, WEE1, DNA-PKcs, and PARP, each of which could theoretically be targeted to strip MYC-driven tumors of their repair advantage. The challenge, the authors note, is that the optimal combination strategy and the biomarkers needed to select the right patients remain undefined.
Early clinical signals: MYC can be targeted in patients
For decades, MYC was considered “undruggable.” It lacks the deep binding pockets that conventional small molecules latch onto, and its interactions with DNA are spread across large, flat protein surfaces. That reputation began to crack with OMO-103, a miniprotein designed to interfere directly with MYC’s ability to bind its obligate partner MAX. A phase 1 trial published in Nature Medicine in 2024 tested OMO-103 in patients with advanced solid tumors who had exhausted standard options. The study established that pharmacologic MYC targeting is feasible in humans, with preliminary signals of activity and a manageable safety profile.
Separately, the ATR inhibitor camonsertib completed a first-in-human trial in patients with DNA damage response-deficient advanced solid tumors. That study, also published in Nature Medicine, provided proof of concept that blocking a key repair-pathway kinase can produce clinical benefit in cancers already carrying DNA repair defects.
Neither trial was designed to test the specific combination hypothesis that emerges from the mechanistic work. But together they confirm that both the upstream target (MYC itself) and a critical downstream repair node (ATR) can be hit with acceptable toxicity. The absence of major unexpected safety signals lowers one barrier to future trials that bring chemotherapy, MYC inhibition, and repair-pathway blockade together in the same regimen.
The gaps that still need closing
Several important questions remain unanswered. The pS62-MYC recruitment data, while mechanistically detailed, comes from a preprint. Laboratory models of genotoxic stress do not replicate the pharmacokinetics, immune interactions, and microenvironmental complexity of chemotherapy in a living patient. Whether pS62-MYC levels at baseline can predict which patients would respond to MYC inhibition or ATR blockade has not been tested in any published clinical dataset.
The TOP2A findings raise a question current data cannot resolve: does MYC-driven TOP2A engagement make anthracycline therapy more effective by creating more initial breaks, or does the accelerated repair that follows cancel out that advantage? The two effects could offset each other in ways that differ by tumor type, MYC expression level, and the specific drug used. In some settings, higher break numbers might briefly outpace repair capacity, tipping cells into apoptosis. In others, a robust homologous recombination response could restore chromosomal integrity before lethal damage accumulates. Resolving that tension will likely require pharmacodynamic studies measuring unrepaired break counts and RAD51 foci in patient biopsies before and after treatment, a type of data that does not yet exist in published form.
The cohesin-loading mechanism adds further complexity. Replication stress caused by MYC could sensitize cells to certain drugs while making them resistant to others, depending on which repair pathways are engaged and how intact checkpoint signaling remains. Cells relying heavily on ATR and CHK1 to manage stalled replication forks might be exquisitely vulnerable to inhibitors of those kinases yet relatively indifferent to PARP blockade if homologous recombination remains functional.
And then there is the question of which patients stand to benefit most. MYC overexpression is common across many cancer types, from Burkitt lymphoma and neuroblastoma, where MYC rearrangements are defining features, to subsets of breast, lung, ovarian, and colorectal cancers. Whether the repair-shield mechanism operates identically across all of these contexts, or whether tissue-specific biology modulates it, is unknown.
Where the field goes from here
The current evidence justifies focused investment but not overreach. MYC clearly does more than drive proliferation. It orchestrates a nuanced response to DNA damage that can blunt the impact of standard chemotherapy. The mechanistic picture, built from the pS62-MYC recruitment data, the TOP2A diffusion work, the cohesin-loading studies, and the integrative review, is internally consistent and generates testable predictions.
The next critical steps are combination trials that layer MYC inhibitors or ATR/CHK1 blockers onto topoisomerase II poisons in patients whose tumors are confirmed MYC-high. Those trials will need to incorporate pharmacodynamic endpoints, such as unrepaired DNA break counts in tumor biopsies, to determine whether the repair shield is actually being dismantled in vivo. Until that data arrives, the concept of disarming MYC’s repair function should be viewed as a promising, mechanistically grounded strategy awaiting rigorous clinical validation, not a practice-changing standard of care.
But the trajectory is clear. For the first time, researchers can describe in molecular detail how MYC protects cancer cells from the drugs meant to destroy them, and they have early-stage tools to block that protection. If the combination hypothesis holds up in patients, it could reshape how oncologists approach some of the most treatment-resistant tumors in medicine.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
